Cancer Research Contributions
At SCRI Oncology Partners, we are dedicated to advancing cancer detection and treatment. Our locally recognized and globally known physicians have contributed to over 170 research journals. As leading oncology research experts, we strive to bridge the gap between cutting-edge scientific discoveries and clinical practice. Our research library serves as an informative platform where you can stay updated on the latest clinical trials, groundbreaking research findings and innovative therapeutic strategies. Together, we can enhance our collaborative efforts to improve patient outcomes and offer hope to those battling cancer.
October 5, 2024
Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
October 2, 2024
Understanding Treatment Decisions and Management for Patients with Advanced Renal Cell Carcinoma Using Hypothetical Case Studies: A Vodcast
April 30, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
December 20, 2023
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
December 19, 2023
Matching-adjusted indirect comparison of PFS and OS comparing ribociclib plus letrozole versus palbociclib plus letrozole as first-line treatment of HR+/HER2- advanced breast cancer
December 13, 2023
Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers
December 10, 2023
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
December 2, 2023
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10
December 1, 2023
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial
November 14, 2023
The Landscape of Alterations from 1407 Ultra-Rare Sarcomas from the AACR GENIE Database: Clinical Implications
November 11, 2023
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON)
November 11, 2023
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer
November 1, 2023
Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial
October 23, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study
October 23, 2023
RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond
October 20, 2023
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
October 19, 2023
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial
October 2, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
October 2, 2023
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor-Positive Breast Cancer
September 26, 2023
Clinical development and management of adverse events associated with FGFR inhibitors
September 25, 2023
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
September 12, 2023
Variant allele frequency: a decision-making tool in precision oncology?
September 10, 2023
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
September 6, 2023
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
September 1, 2023
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
September 1, 2023
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
August 15, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients
August 15, 2023
Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
August 11, 2023
Evolving perspectives on the treatment of HR+/HER2+ metastatic breast cancer
August 9, 2023
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study
August 6, 2023
Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series
August 4, 2023
SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy
August 4, 2023
Sodium fluoride (Na18F) PET Response Criteria in Solid Tumors (NAFCIST): a framework for response assessment in bone tumors
July 29, 2023
For what it's worth: the complex area of medicine value assessment
July 29, 2023
Searching for clinical trials in oncology: finding a path through the maze
July 28, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours
July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results
July 24, 2023
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges
July 19, 2023
Weight Gain in Cancer Patients Treated with Brain Penetrant RET-selective Inhibitors
July 5, 2023
A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
July 5, 2023
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
June 30, 2023
Cracking KRASG12C across all solid tumors: the new kid on the block for tissue-agnostic precision medicine
June 27, 2023
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
June 24, 2023
Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
June 21, 2023
Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
June 12, 2023
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
June 6, 2023
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01
June 1, 2023
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results
June 1, 2023
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
June 1, 2023
A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors
June 1, 2023
Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study
May 29, 2023
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer
May 26, 2023
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID)
May 25, 2023
Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond
May 12, 2023
A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors
May 2, 2023
Novel Estrogen Receptor-Targeted Agents for Breast Cancer
May 1, 2023
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
April 26, 2023
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation
March 29, 2023
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
March 29, 2023
The evolving landscape of antibody-drug conjugates in gynecologic cancers
March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study
March 4, 2023
Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours
March 3, 2023
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors
March 3, 2023
Novel endocrine therapy agents in ER-positive, HER2-negative breast cancer
March 1, 2023
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
February 27, 2023
The National Clinical Trials Network: A Valuable and Undervalued Resource
February 20, 2023
VISTA expression and patient selection for immune-based anticancer therapy
February 8, 2023
Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study
February 7, 2023
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
February 1, 2023
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
January 26, 2023
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659)
January 14, 2023
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
January 9, 2023
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial
January 1, 2023
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis
January 1, 2023
Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817
December 21, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
December 19, 2022
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2
November 11, 2022
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis
November 7, 2022
Targeting HER2-positive breast cancer: advances and future directions
November 4, 2022
Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
November 3, 2022
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study
Cancer Type
Treatment
Contact Us
Whether you are newly diagnosed, previously treated or seeking additional care or research options, we are here to support you every step of the way.
Contact Us
Whether you are newly diagnosed, previously treated or seeking additional care or research options, we are here to support you every step of the way.
Contact Us
Whether you are newly diagnosed, previously treated or seeking additional care or research options, we are here to support you every step of the way.